Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant complement factor H - Disc Medicine

Next Previous
Drug Profile

Recombinant complement factor H - Disc Medicine

Alternative Names: GEM-103; rCFH; recombinant human CFH - Disc Medicine; rhCFH - Disc Medicine

Latest Information Update: 02 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gemini Therapeutics
  • Developer Disc Medicine
  • Class Eye disorder therapies; Recombinant proteins
  • Mechanism of Action Complement factor H replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry age-related macular degeneration; Wet age-related macular degeneration

Most Recent Events

  • 29 Dec 2022 Gemini Therapeutics has merged with Disc Medicine to form Disc Medicine
  • 01 Mar 2022 Gemini Therapeutics has pending patent cooperation treaty (PCT) application directed to dosage regimens for treating inflammatory ocular diseases using GEM 103 in the US and Undisclosed foreign locations
  • 01 Mar 2022 Gemini Therapeutics has pending patent cooperation treaty (PCT) application directed to methods of treating age-related macular degeneration using GEM 103 in patients who carry certain CFH genetic mutations, in the US and Undisclosed foreign locations

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top